Loading…
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $96M | $-12M | $-5M | $0M | -1.2% | 28.9% | -77.2% |
| 2024 | $75M | $4M | $-20M | $5M | -5.8% | 9.7% | -70.3% |
| 2023 | $68M | $-7M | $-68M | $-19M | -20.1% | -10.8% | -51.4% |
| 2022 | $76M | $6M | $-140M | $-19M | -38.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 76.24 | 68.02 | 74.65 | 96.21 |
| Cost Of Revenue | - | 29.33 | 26.70 | 24.55 | 34.10 |
| Gross Profit | - | 46.91 | 41.32 | 50.10 | 62.12 |
| Operating Expense | - | 57.59 | 60.72 | 54.57 | 78.72 |
| Operating Income | - | -10.68 | -19.40 | -4.48 | -16.60 |
| EBITDA | - | 5.80 | -7.10 | 4.18 | -11.92 |
| EBIT | - | -10.68 | -19.40 | -4.48 | -16.60 |
| Pretax Income | - | -4.85 | -12.22 | -8.82 | -12.08 |
| Tax Provision | - | -5.24 | -0.06 | -0.04 | 0.05 |
| Net Income | - | -139.80 | -68 | -20.18 | -4.60 |
| Net Income Common Stockholders | - | -139.80 | -68 | -20.18 | -4.60 |
| Total Expenses | - | 86.92 | 87.41 | 79.12 | 112.82 |
| Research And Development | - | 8.67 | 5.52 | 4.75 | 23.09 |
| Selling General And Administration | - | 44.93 | 54.17 | 49.56 | 55.37 |
| Normalized EBITDA | - | 0.34 | -14.41 | 8.26 | -11.92 |
| Normalized Income | - | -4.84 | -19.39 | -4.73 | -12.13 |
| Market Cap | 1,032.65 | 1,032.65 | 1,032.65 | 1,032.65 | 1,032.65 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioLife Solutions, Inc.this co. | BLFS | - | -224.73 | 2.78 | -1.2% | -85.40 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| - |
| - |
| - |
| - |
| - |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |